Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Change in Acquisitions & Divestments (2021 - 2025)

Historic Change in Acquisitions & Divestments for Foghorn Therapeutics (FHTX) over the last 5 years, with Q3 2025 value amounting to $39.6 million.

  • Foghorn Therapeutics' Change in Acquisitions & Divestments fell 3762.61% to $39.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $258.5 million, marking a year-over-year increase of 2063.64%. This contributed to the annual value of $232.5 million for FY2024, which is 587.36% up from last year.
  • According to the latest figures from Q3 2025, Foghorn Therapeutics' Change in Acquisitions & Divestments is $39.6 million, which was down 3762.61% from $76.0 million recorded in Q2 2025.
  • Over the past 5 years, Foghorn Therapeutics' Change in Acquisitions & Divestments peaked at $94.5 million during Q2 2021, and registered a low of $19.0 million during Q2 2022.
  • Moreover, its 5-year median value for Change in Acquisitions & Divestments was $54.6 million (2022), whereas its average is $53.0 million.
  • In the last 5 years, Foghorn Therapeutics' Change in Acquisitions & Divestments crashed by 7988.78% in 2022 and then soared by 30301.58% in 2023.
  • Quarter analysis of 5 years shows Foghorn Therapeutics' Change in Acquisitions & Divestments stood at $20.0 million in 2021, then soared by 90.5% to $38.1 million in 2022, then grew by 16.17% to $44.3 million in 2023, then surged by 41.02% to $62.4 million in 2024, then plummeted by 36.6% to $39.6 million in 2025.
  • Its Change in Acquisitions & Divestments was $39.6 million in Q3 2025, compared to $76.0 million in Q2 2025 and $80.6 million in Q1 2025.